- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis (2010)
"The accumulation of the cladribine nucleotide produces rapid and sustained reductions in CD4+ and CD8+ cells and rapid, though more transient, effects on CD19+ B cells, with relative sparing of other immune cells."
i wondered what vitamin d3 might be up to in the cd19+ department.
scholar search landed here:
- Vitamin D3 and Its Synthetic Analogs Inhibit the Spontaneous in Vitro Immunoglobulin Production by SLE-Derived PBMC (2001)
Incubating SLE PBMC with 1,25 D3 compounds significantly reduced proliferation, polyclonal and anti-dsDNA IgG production, and the percentages of CD3+/DR+ T and B (CD19+) cells..
- Low serum concentrations of 1,25-dihydroxyvitamin D in human magnesium deficiency (1985)
"mean serum 25OHD concentration was in the low normal range (13.2 +/- 1.5 ng/ml) before magnesium administration and did not significantly change after this therapy (14.8 +/- 1.5 ng/ml)" ...
"After magnesium therapy, only 5 of the patients had a rise in the serum 1,25-(OH)2D concentration into or above the normal range"...
"serum vitamin D-binding protein concentration, assessed in 11 patients, was low (273 +/- 86 micrograms/ml) before magnesium therapy, but normalized (346 +/- 86 micrograms/ml) after magnesium repletion."
results of a random thought re poss cladribine interactions with magnesium
- Revisiting the role of cladribine in acute myeloid leukemia: An improvement on past accomplishments or more old news? (2014)
https://onlinelibrary.wiley.com/doi/ful ... /ajh.23862
"Table 1. Proposed Mechanisms of Action of Cladribine Across Numerous Malignancies ...
Inhibition of DNA repair results in DNA strand breaks
• Activates calcium and magnesium dependent endonuclease"
for now, i'm happy with having recently boosted serum 25OHD3 from 50 to 166 nmol/l
not forgetting plenty of dietary and supplemental magnesium etc.